PPD LICENSES GGTASE INHIBITOR COMPOUNDS TO DUKE
UNIVERSITY.
PPD, Inc. (Nasdaq: PPDI), Wilmington, N.C., has signed an agreement
to exclusively license to Duke University the development rights to
PPD's patented portfolio of geranylgeranyl transferase . . .
MARC GETS U.S. PATENT FOR BETULINOL DERIVATIVES FOR
CANCER.
Marc Pharmaceuticals, Inc. (OTC:MPMA, MPMAW, MPMAZ), Stamford,
Conn., has been granted U.S. Patent No. 6,890,533 for Betulinol
Derivatives. Owned by Cornell Research Foundation and licensed to . . .
NUVELO BEGINS PHASE 3 TRIAL OF ALFIMEPRASE FOR "LEG
ATTACK".
Nuvelo Inc., (Nasdaq: NUVO), Sunnyvale, Calif., has begun patient
enrollment in a Phase 3 trial of its lead product candidate,
alfimeprase, for the treatment of acute peripheral arterial . . .
IKONISYS SIGNS LICENSE/SUPPY PACTS WITH ABBOTT.
Ikonisys, Inc., New Haven, N.J., has executed two agreements that
grant Ikonisys license and supply rights to certain DNA probe technology
for use with the proprietary Celloptics(TM) technology . . .
COTHERIX SELECTS ACCREDO THERAPEUTICS TO DISTRIBUTE
VENTAVIS.
Accredo Health, Incorporated (NASDAQ: ACDO), Memphis, Tenn., has
announced that one of its three primary divisions, Accredo Therapeutics,
has been selected by CoTherix, Inc. (NASDAQ: CTRX) as one . . .
ZIOPHARM INITIATES 2ND PHASE I STUDY OF ZIO-101.
ZIOPHARM, Inc., Charlestown, Mass., has initiated its second phase
I study to assess safety and dosing of ZIO-101, the company's
proprietary small molecule organic arsenic. This trial is . . .
MAP PHARMACEUTICALS APPOINTS NELSON PRESIDENT/CEO.
MAP Pharmaceuticals, Inc., Mountain View, Calif., a developer of
novel inhaled drug products, has announced the appointment of Timothy S.
Nelson as the company's new president and chief executive . . .
LIAD SCIENTISTS IDENTIFY BACTERIA TRIGGERING IMMUNE
RESPONSE.
Researchers at the La Jolla Institute for Allergy & Immunology
(LIAI), San Diego, have identified the bacteria, Sphingomonas, as
containing a glycolipid which naturally triggers an immune response . . .
BOLEX/CENTOCOR TO MANUFACTURE PROTEINS USING LEX SYSTEM.
Biolex, Inc., Pittsboro, N.C., a privately held protein
therapeutics company, has announced a broad-based, multi- leveled
strategic alliance with Centocor, Inc., a leading . . .
PATENT AWARDED TO UNIGEN FOR NOVEL POLICOSANOL.
Unigen Pharmaceuticals, Inc., Lacey, Wash., a research and
development facility and supplier of proprietary, biologically active
plant-derived ingredients to the natural products and . . .
GENVEC GETS FDA CLEARANCE TO RESUME PHASE II TNFERADE
TRIAL.
GenVec, Inc. (Nasdaq:GNVC), Gaithersburg, Md., has announced that
the FDA has informed the company that it may resume its Phase II
clinical trial of TNFerade(TM) in rectal cancer. This trial will . . .
THRESHOLD GETS POSITIVE RESULTS FROM TH-070 PHASE 2 BPH
TRIAL.
Threshold Pharmaceuticals Inc., Redwood City, Calif. has announced
follow up results of a Phase 2 study of its investigational drug
candidate, TH-070 (lonidamine) for the treatment of benign . . .
INFINITY'S IPI-504 PROVIDES PROMISING ANTICANCER
ACTIVITY.
Infinity Pharmaceuticals,Inc., Anaheim, Calif., has announced
positive preclinical data on the company's novel investigational
compound IPI-504, a potent inhibitor of Heat Shock Protein 90 . . .
FDA ACCEPTS XYREM SNDA FOR REVIEW.
Orphan Medical, Inc. (Nasdaq:ORPH) has announced that the Food and
Drug Administration (FDA) has accepted for filing the company's
Supplemental New Drug Application (sNDA) for Xyrem(R) (sodium . . .
ORPHAN MEDICAL SUBMITS XYREM SNDA TO FDA.
Orphan Medical, Inc. (Nasdaq:ORPH), Minneapolis, has submitted a
Supplemental New Drug Application (sNDA) for Xyrem(R) (sodium oxybate)
oral solution to the Food and Drug Administration (FDA). . . .
DYNAVAX INITIATES PHASE 3 TRIAL FOR HEPATITIS B VACCINE.
Dynavax Technologies Corporation (Nasdaq: DVAX), Berkeley, Calif.,
has initiated a pivotal Phase 3 clinical trial of its hepatitis B (HBV)
vaccine. The pivotal Phase 3 trial is designed to compare . . .
ALNYLAM INITIATES RNAI THERAPEUTIC PROGRAM FOR PANDEMIC
FLU.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Cambridge, Mass., a
RNAi therapeutics company, has announced a collaboration with
researchers from the University of Georgia to discover and develop . . .
GLYCOFI/CENTOCOR EVALUATE GLYCOPROTEIN PRODUCTION.
GlycoFi, Lebanon, NH, has initiated a collaboration with Centocor,
Inc, to determine the feasibility of producing a Centocor protein using
GlycoFi's proprietary yeast-based glycoprotein . . .
BIOMARKER BEGINS PILOT STUDY OF BREAST CANCER BLOOD TEST.
Biomarker Technologies LLC, Phoenix, a worldwide technology
provider of the blood diagnostic test for the detection of breast cancer
called the BT Test(TM), has begun a pilot study of the test in . . .
IGC EXPO RELEASES GENE PROFILES FOR 60 TUMOR SPECIMENS.
The International Genomics Consortium's (IGC) Expression
Project for Oncology (expO) has released clinically annotated gene
expression profiles for 60 tumor specimens, completing the initial . . .
|
|